Paragon Gene Therapy, a unit of Catalent Biologics

About Paragon Gene Therapy, a unit of Catalent Biologics

Paragon Gene Therapy is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon’s aim is to build strong client partnerships with the world’s best biotech and pharma companies, focusing on transformative technologies, including, gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics. Paragon's cGMP capabilities include fully-segregated mammalian, virus, and microbial facilities as well as small-batch aseptic fill-finish. In business over 25 years, Paragon’s scientists, engineers, quality systems personnel and project managers have the right experience to guide our clients through process development to GMP manufacturing for clinical trials and eventual commercial launch.

Paragon Gene Therapy offers employees a unique opportunity to not only develop their technical & functional skills but to also develop their understanding of how their work truly impacts the success of the organization.  In the next few years, Paragon Gene Therapy, will triple in size allowing individual and team growth and the ability to evolve current practices.  Opportunity to broaden each individual’s capability positively impacts the organizations ability to deliver stronger relationships to our clients furthering our goals as best in class CDMO.  Our Scientists, Engineers, Quality Professionals and many business support teams have a rare opportunity to build an organization to rise up and meet the needs of pharmaceutical & biotechnology companies solving the world’s healthcare needs.  Come be part of this amazing team!

Key management listings

• Peter Buzy – President &  CEO
• William Thomas, Jr, PhD –  Chief Technical Officer
• Philip Wills, PhD – Chief Commercial Officer
• Gerard Fleury – Chief Financial Officer
• John Conner, MS – Chief Manufacturing Officer
• Randy Henrickson, MS – SVP, GMP Manufacturing
• Deborah Wild - SVP, Quality and Regulatory Affairs
• George Buchman, PhD - Vice President, Process Development
• Ruby Hofmann - SVP, Human Resources and Organizational  Development

Additional location: 

7555 Harmans Road

Harmans, Maryland 21077

United States